ID28376A
(id)
*
|
1998-11-10 |
2001-05-17 |
Janssen Pharmaceutica Nv |
Pirimidina yang menghambat replikasi hiv
|
GB9914258D0
(en)
*
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
DE19945982A1
(de)
*
|
1999-09-24 |
2001-03-29 |
Knoll Ag |
Geschwindigkeitsbestimmte Partikel
|
CZ300712B6
(cs)
|
1999-09-24 |
2009-07-22 |
Janssen Pharmaceutica N. V. |
Cásticová farmaceutická kompozice, pevná disperze a farmaceutická dávková forma, zpusoby jejich prípravy a použití a obchodní balení s jejich obsahem
|
JP2003511378A
(ja)
|
1999-10-07 |
2003-03-25 |
アムジエン・インコーポレーテツド |
トリアジン系キナーゼ阻害薬
|
CN1429222A
(zh)
|
2000-02-17 |
2003-07-09 |
安姆根有限公司 |
激酶抑制剂
|
CA2407754C
(en)
|
2000-05-08 |
2009-09-15 |
Janssen Pharmaceutica N.V. |
Prodrugs of hiv replication inhibiting pyrimidines
|
WO2001085700A2
(en)
|
2000-05-08 |
2001-11-15 |
Janssen Pharmaceutica N.V. |
Hiv replication inhibiting pyrimidines and triazines
|
US7418471B2
(en)
*
|
2000-11-01 |
2008-08-26 |
Snapnames.Com, Inc. |
Domain name acquisition and management system and method
|
NZ529654A
(en)
|
2001-05-29 |
2005-12-23 |
Schering Ag |
CDK inhibiting pyrimidines, production thereof and their use as medicaments
|
US6958211B2
(en)
|
2001-08-08 |
2005-10-25 |
Tibotech Bvba |
Methods of assessing HIV integrase inhibitor therapy
|
US8101629B2
(en)
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
JO3429B1
(ar)
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
مشتقات برميدينات مثبطة فيروس الايدز
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
DK1438053T3
(da)
|
2001-10-17 |
2008-12-08 |
Boehringer Ingelheim Pharma |
Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
|
EP1453516A2
(de)
|
2001-10-17 |
2004-09-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
|
HUP0402106A3
(en)
|
2001-11-01 |
2009-07-28 |
Janssen Pharmaceutica Nv |
Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
|
IL161661A0
(en)
|
2001-11-01 |
2004-09-27 |
Janssen Pharmaceutica Nv |
Amide derivatives as glycogen synthase kinase 3-beta inhibitors
|
SE0104140D0
(sv)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
BR0307624A
(pt)
|
2002-03-13 |
2005-01-11 |
Janssen Pharmaceutica Nv |
Inibidores de histona desacetilase
|
CN1305850C
(zh)
|
2002-03-13 |
2007-03-21 |
詹森药业有限公司 |
作为组蛋白脱乙酰酶新颖抑制剂的磺酰基氨基衍生物
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
MXPA04010778A
(es)
*
|
2002-05-03 |
2005-03-07 |
Janssen Pharmaceutica Nv |
Microemulsiones polimericas.
|
AR039540A1
(es)
*
|
2002-05-13 |
2005-02-23 |
Tibotec Pharm Ltd |
Compuestos microbicidas con contenido de pirimidina o triazina
|
AR040456A1
(es)
|
2002-06-27 |
2005-04-06 |
Bristol Myers Squibb Co |
Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
|
IL166241A
(en)
|
2002-07-29 |
2011-12-29 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds for use in the treatment of autoimmune diseases
|
ES2422196T3
(es)
*
|
2002-08-09 |
2013-09-09 |
Janssen Pharmaceutica Nv |
Procesos para la preparación de 4-4-4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)aminobenzonitrilo
|
CN1703200B
(zh)
*
|
2002-09-20 |
2012-02-29 |
奥尔制药公司 |
隔离亚单元和相关组合物及方法
|
EP1565446A1
(en)
*
|
2002-11-28 |
2005-08-24 |
Schering Aktiengesellschaft |
Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
|
DE602004009295T2
(de)
|
2003-01-14 |
2008-07-03 |
Arena Pharmaceuticals, Inc., San Diego |
1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
|
AP2005003365A0
(en)
*
|
2003-02-07 |
2005-09-30 |
Janssen Pharmaceutica Nv |
Hiv inhibiting 1, 2, 4-triazines.
|
AU2004210081B2
(en)
|
2003-02-07 |
2009-11-26 |
Janssen Pharmaceutica N.V. |
Pyrimidine derivatives for the prevention of HIV infection
|
JP4634367B2
(ja)
*
|
2003-02-20 |
2011-02-16 |
スミスクライン ビーチャム コーポレーション |
ピリミジン化合物
|
CL2004000303A1
(es)
*
|
2003-02-20 |
2005-04-08 |
Tibotec Pharm Ltd |
Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
WO2005011702A1
(en)
*
|
2003-07-17 |
2005-02-10 |
Tibotec Pharmaceuticals Ltd. |
Process for preparing particles containing an antiviral
|
RS53109B
(en)
|
2003-07-30 |
2014-06-30 |
Rigel Pharmaceuticals Inc. |
2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
|
AP2006003517A0
(en)
*
|
2003-09-25 |
2006-02-28 |
Janssen Pharmaceutica Nv |
Hiv replication purine derivatives.
|
EP1728186A2
(en)
|
2004-03-02 |
2006-12-06 |
Virco Bvba |
Estimation of clinical cut-offs
|
EP1598343A1
(de)
*
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
2-Arylaminopyrimidine als PLK Inhibitoren
|
AP2336A
(en)
|
2004-07-28 |
2011-12-08 |
Janssen Pharmaceutica Nv |
Subsituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase.
|
CA2575002C
(en)
|
2004-08-10 |
2015-01-20 |
Janssen Pharmaceutica N.V. |
Hiv inhibiting 1,2,4-triazin-6-one derivatives
|
CA2577467C
(en)
*
|
2004-09-30 |
2013-05-28 |
Tibotec Pharmaceuticals Ltd. |
Hiv inhibiting 5-heterocyclyl pyrimidines
|
CA2573976C
(en)
*
|
2004-09-30 |
2014-04-29 |
Tibotec Pharmaceuticals Ltd. |
Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
|
ATE542802T1
(de)
*
|
2004-09-30 |
2012-02-15 |
Tibotec Pharm Ltd |
Hiv-inhibierende 5-substituierte pyrimidine
|
ES2508766T3
(es)
|
2004-10-29 |
2014-10-16 |
Janssen R&D Ireland |
Derivados de pirimidina bicíclicos que inhiben el VIH
|
EP1812069A2
(en)
*
|
2004-11-08 |
2007-08-01 |
Boehringer Ingelheim International GmbH |
Method for treating hiv infection through co-administration of tipranavir and etravirine
|
EP1814878B1
(en)
|
2004-11-24 |
2012-01-04 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
MX2007007189A
(es)
|
2005-01-19 |
2010-09-28 |
Rigel Pharmaceuticals Inc |
Prodrogas de compuestos de 2,4-pirimidindiamina y sus usos.
|
ATE523498T1
(de)
*
|
2005-01-27 |
2011-09-15 |
Tibotec Pharm Ltd |
Hiv-inhibierende 2-(4- cyanophenylamino)pyrimidinderivate
|
BRPI0607455A2
(pt)
|
2005-02-16 |
2009-09-01 |
Astrazeneca Ab |
composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
|
MX2007010051A
(es)
*
|
2005-02-18 |
2007-09-21 |
Tibotec Pharm Ltd |
Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana.
|
WO2006094930A1
(en)
*
|
2005-03-04 |
2006-09-14 |
Tibotec Pharmaceuticals Ltd. |
Hiv inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines
|
BRPI0610184A2
(pt)
|
2005-05-16 |
2012-09-25 |
Astrazeneca Ab |
composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
|
DK1888537T3
(da)
*
|
2005-05-26 |
2013-12-09 |
Janssen R & D Ireland |
Fremgangsmåde til fremstilling af 4[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitril
|
EP1904457B1
(en)
|
2005-06-08 |
2017-09-06 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
CA2628863A1
(en)
*
|
2005-10-06 |
2007-04-19 |
University Of Massachusetts |
Composition and synthesis of new reagents for inhibition of hiv replication
|
TW200800963A
(en)
|
2005-10-28 |
2008-01-01 |
Astrazeneca Ab |
Chemical compounds
|
DK1981875T3
(da)
|
2006-01-19 |
2014-07-14 |
Janssen Pharmaceutica Nv |
Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
|
DK1981874T3
(da)
|
2006-01-19 |
2009-09-28 |
Janssen Pharmactuica N V |
Aminophenylderivater som nye inhibitorer af histondeacetylase
|
JP5247470B2
(ja)
|
2006-01-19 |
2013-07-24 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
|
WO2007098507A2
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
MX2008012576A
(es)
|
2006-03-30 |
2008-10-10 |
Tibotec Pharm Ltd |
Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
|
SI2004641T1
(sl)
|
2006-03-30 |
2011-02-28 |
Tibotec Pharm Ltd |
HIV inhibirajoči 5-(hidroksimetilen in aminometilen) substituirani pirimidini
|
PE20080068A1
(es)
|
2006-05-15 |
2008-03-17 |
Boehringer Ingelheim Int |
Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
|
RS52053B
(en)
|
2006-06-06 |
2012-04-30 |
Tibotec Pharmaceuticals |
PROCESS FOR PREPARATION OF SPRAY DRY FORMULATIONS TMC125
|
DK2484346T3
(en)
|
2006-06-19 |
2017-04-24 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical compositions
|
WO2008063301A2
(en)
*
|
2006-10-11 |
2008-05-29 |
Alpharma, Inc. |
Pharmaceutical compositions
|
EP2104491B1
(en)
|
2006-12-06 |
2017-02-22 |
Janssen Sciences Ireland UC |
Hydrobromide salt of an anti-hiv compound
|
BRPI0722079B8
(pt)
|
2006-12-29 |
2021-05-25 |
Janssen R & D Ireland |
pirimidinas 5,6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
|
MX2009007005A
(es)
*
|
2006-12-29 |
2009-07-09 |
Tibotec Pharm Ltd |
Pirimidinas 6-sustituidas que inhiben el virus de inmunodeficiencia humana.
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
US8410124B2
(en)
|
2007-10-18 |
2013-04-02 |
Concert Pharmaceuticals Inc. |
Deuterated etravirine
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20090196890A1
(en)
*
|
2007-12-17 |
2009-08-06 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical compositions
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
WO2009143389A1
(en)
|
2008-05-21 |
2009-11-26 |
Ariad Pharmaceuticals, Inc. |
Phosphorous derivatives as kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
EP2361248B1
(en)
|
2008-06-27 |
2018-09-19 |
Celgene CAR LLC |
Heteroaryl compounds and uses thereof
|
AR073760A1
(es)
*
|
2008-10-03 |
2010-12-01 |
Astrazeneca Ab |
Derivados heterociclicos y metodos de uso de los mismos
|
US20110071158A1
(en)
*
|
2009-03-18 |
2011-03-24 |
Boehringer Ingelheim International Gmbh |
New compounds
|
BRPI1012666B8
(pt)
|
2009-03-30 |
2021-05-25 |
Janssen R&D Ireland |
cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
|
EP2440559B1
(en)
|
2009-05-05 |
2018-01-10 |
Dana-Farber Cancer Institute, Inc. |
Egfr inhibitors and methods of treating disorders
|
WO2010131118A2
(en)
*
|
2009-05-12 |
2010-11-18 |
Pliva Hrvatska D.O.O. |
Polymorphs of etravirine and processes for preparation thereof
|
JP5406934B2
(ja)
|
2009-06-22 |
2014-02-05 |
エムキュア ファーマシューティカルズ リミテッド |
ジアリールピリミジン非ヌクレオシド系逆転写酵素阻害剤の合成方法
|
US8153790B2
(en)
|
2009-07-27 |
2012-04-10 |
Krizmanic Irena |
Process for the preparation and purification of etravirine and intermediates thereof
|
GR1007010B
(el)
|
2009-10-08 |
2010-10-07 |
Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), |
Ινσουλινοειδη πεπτιδια
|
RS54865B1
(sr)
|
2010-06-04 |
2016-10-31 |
Hoffmann La Roche |
Derivati aminopirimidina kao modulatori lrrk2
|
US8598341B2
(en)
|
2010-06-28 |
2013-12-03 |
Hetero Research Foundation |
Process for etravirine intermediate and polymorphs of etravirine
|
MX336875B
(es)
|
2010-08-10 |
2016-02-04 |
Celgene Avilomics Res Inc |
Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
|
BR112013008100A2
(pt)
|
2010-09-22 |
2016-08-09 |
Arena Pharm Inc |
"moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
|
EP2635285B1
(en)
|
2010-11-01 |
2017-05-03 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
PH12013500870A1
(en)
|
2010-11-01 |
2013-06-03 |
Celgene Car Llc |
Heterocyclic compounds and uses thereof
|
HUE037844T2
(hu)
|
2010-11-10 |
2018-09-28 |
Genentech Inc |
Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
|
EP2637502B1
(en)
|
2010-11-10 |
2018-01-10 |
Celgene CAR LLC |
Mutant-selective egfr inhibitors and uses thereof
|
EP2702045B1
(en)
|
2011-04-26 |
2017-10-18 |
Mylan Laboratories Ltd. |
Novel process for the preparation of etravirine
|
BR112013027734A2
(pt)
|
2011-05-04 |
2017-08-08 |
Ariad Pharma Inc |
compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica
|
WO2012170647A1
(en)
*
|
2011-06-09 |
2012-12-13 |
Assia Chemical Industriew Ltd. |
Process for the preparation of etravirine and intermediates in the synthesis thereof
|
US8729079B2
(en)
|
2011-08-23 |
2014-05-20 |
Endo Pharmaceuticals Inc. |
Pyrimido-pyridazinone compounds and methods of use thereof
|
WO2013059572A1
(en)
|
2011-10-19 |
2013-04-25 |
Assia Chemical Industries Ltd. |
Process for the preparation of etravirine and intermediates in the synthesis thereof
|
WO2013063401A1
(en)
|
2011-10-28 |
2013-05-02 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
WO2013109354A2
(en)
*
|
2011-12-07 |
2013-07-25 |
Texas Southern University |
Etravirine formulations and uses thereof
|
PL2825042T3
(pl)
|
2012-03-15 |
2019-02-28 |
Celgene Car Llc |
Sole inhibitora kinazy receptora czynnika wzrostu naskórka
|
US9056839B2
(en)
|
2012-03-15 |
2015-06-16 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
JP6469567B2
(ja)
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Egfr発動性がんの細胞増殖阻害用化合物
|
US20150336900A1
(en)
*
|
2012-10-29 |
2015-11-26 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Process for the Synthesis of Etravirine and Its Intermediates
|
WO2014072419A1
(en)
|
2012-11-08 |
2014-05-15 |
Universiteit Antwerpen |
Novel anti-hiv compounds
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
HK1216721A1
(zh)
|
2012-12-21 |
2016-12-02 |
Verlyx Pharma Inc. |
治疗肝脏疾病或病状的用途和方法
|
ES2805359T3
(es)
|
2013-02-08 |
2021-02-11 |
Celgene Car Llc |
Inhibidores de ERK y sus usos
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
ES2741785T3
(es)
|
2014-08-13 |
2020-02-12 |
Celgene Car Llc |
Formas y composiciones de un inhibidor de ERK
|
CA3002540C
(en)
|
2015-01-06 |
2023-11-07 |
Arena Pharmaceuticals, Inc. |
Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
|
CN104926829A
(zh)
*
|
2015-06-08 |
2015-09-23 |
山东大学 |
一种噻吩并嘧啶类衍生物及其制备方法和应用
|
EP3939965A1
(en)
|
2015-06-22 |
2022-01-19 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
|
KR20190140011A
(ko)
|
2017-04-28 |
2019-12-18 |
아사나 바이오사이언시스 엘엘씨 |
아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
|
EP3801459B1
(en)
|
2018-06-06 |
2024-08-07 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
CN110066273A
(zh)
*
|
2019-06-05 |
2019-07-30 |
山东大学 |
一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
|
AU2020300619A1
(en)
|
2019-07-03 |
2022-01-27 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
CN111217833B
(zh)
*
|
2020-02-21 |
2021-03-16 |
山东大学 |
噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
|
CN111875548A
(zh)
*
|
2020-07-16 |
2020-11-03 |
山东大学 |
一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
|